Development of a RVFV ELISA that can distinguish infected from vaccinated animals

Virol J. 2009 Aug 13:6:125. doi: 10.1186/1743-422X-6-125.

Abstract

Background: Rift Valley Fever Virus is a pathogen of humans and livestock that causes significant morbidity and mortality throughout Africa and the Middle East. A vaccine that would protect animals from disease would be very beneficial to the human population because prevention of the amplification cycle in livestock would greatly reduce the risk of human infection by preventing livestock epizootics. A mutant virus, constructed through the use of reverse genetics, is protective in laboratory animal models and thus shows promise as a potential vaccine. However, the ability to distinguish infected from vaccinated animals is important for vaccine acceptance by national and international authorities, given regulations restricting movement and export of infected animals.

Results: In this study, we describe the development of a simple assay that can be used to distinguish naturally infected animals from ones that have been vaccinated with a mutant virus. We describe the cloning, expression and purification of two viral proteins, and the development of side by side ELISAs using the two viral proteins.

Conclusion: A side by side ELISA can be used to differentiate infected from vaccinated animals. This assay can be done without the use of biocontainment facilities and has potential for use in both human and animal populations.

Publication types

  • Evaluation Study

MeSH terms

  • Africa
  • Animals
  • Antibodies, Viral / blood*
  • Antigens, Viral* / genetics
  • Diagnosis, Differential
  • Enzyme-Linked Immunosorbent Assay / methods*
  • Humans
  • Mice
  • Middle East
  • Recombinant Proteins / genetics
  • Rift Valley Fever / diagnosis
  • Rift Valley Fever / immunology
  • Rift Valley Fever / prevention & control
  • Rift Valley Fever / veterinary*
  • Rift Valley fever virus / immunology*
  • Viral Vaccines / immunology*

Substances

  • Antibodies, Viral
  • Antigens, Viral
  • Recombinant Proteins
  • Viral Vaccines